Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

Features
Efficacy and improved tolerability of Hypericum perforatum extract, WS 5570, compared to paroxetine in patients with moderate to severe depression

16 Mar 05

Depression is the most common mental disorder worldwide affecting around 120 million people globally. The depression market is the largest segment of the CNS market with global sales of US$15.5 billion in 2003 although this figure is dropping as generic equivalents of past blockbusters are launched. Although the depression market has matured, key areas of unmet clinical need will have to be addressed in order to drive further growth of the market. These include improvements in the safety/tolerab
LeadDiscovery

Valeant Pharmaceuticals' remofovir mesylate, an improved adefovir prodrug for targeted and tolerable treatment of hepatitis B (HBV) infection

16 Mar 05

According to the WHO, 350-400 million individuals are chronically infected with the hepatitis B virus (HBV). Chronic infection with hepatitis viruses causes cirrhosis and hepatocellular carcinoma, both devastating diseases with few treatments and the demand for effective treatments for hepatitis infection is therefore high. Lamivudine dominates first-line therapy for HBV (see our feature on hepatitis B & C). Gilead's Adefovir prodrug (Hepsera) represent a second line option although nephrotoxici
LeadDiscovery

Long term beta adrenergic receptor blockade following myocardial infarction promotes myocardial angiogenesis

16 Mar 05

Beta blockers reduce heart rate and myocardial contractility thereby reducing myocardial work load. Diastolic perfusion time is also lengthened by beta blockers supporting the use of this drug class as acute and chronic treatment following myocardial infarction. Studies have demonstrated that beta blockers can reduce total mortality, nonfatal myocardial infarction and sudden death in patients who have already suffered a myocardial infarction by 20-30%. Despite the potential benefit of beta block
LeadDiscovery

Eisai's retinoic acid (RAR)-alpha receptor agonist as a candidate therapy for the treatment of lupus nephritis

16 Mar 05

Lupus is a chronic inflammatory disease that can affect various parts of the body, especially the skin, joints, blood, and kidneys. For most people, lupus is a mild disease affecting only a few organs. For others, it may cause serious and even life-threatening problems. In particular lupus nephritis claim a significant number of lives. More than 16,000 Americans develop lupus each year. It is estimated that 500,000 to 1.5 million Americans have been diagnosed with lupus. Current treatments focus
LeadDiscovery

The Best of Both Worlds

08 Mar 05

Imagine the benefits of working for a global organisation which turns over over £4 billion per year worldwide but is primarily family owned and complete with family values? This is exactly what Merck offers.
Pharmaceutical Field

Sankyo and Daiichi plans show Japanese consolidation goes on

04 Mar 05

Sankyo and Daiichi Pharmaceutical are considering merging in October 2005 to become Japan's number two drugmaker, as competition in the market continues to intensify. Following the announcement of mergers between Yamanouchi and Fujisawa, and Dainippon and Sumitomo, will continuous domestic consolidation ensure a place for global integration in the face of western pressure?
Datamonitor

Bipolar Disorder

03 Mar 05

Bipolar affective disorder – previously referred to as manic depression – is a psychiatric disorder affecting at least 1% of the UK population, and depending on the definition used, may affect as many as 5% of the population. A recent World Health Organization analysis of the major global causes of disability, economic and social burden, indicated that bipolar affective disorders are ranked in the top ten, and account for 2.5% of total years lost to disability across all age groups.
CSF Medical Communications

Emerging oncology treatments: A focus on targeted therapeutics, supergeneric reformulations and supportive care

02 Mar 05

The oncology market is the third largest pharmaceutical market, behind the cardiovascular and CNS therapy areas, and is currently experiencing strong growth. Worth an estimated $35 billion in 2003, analysts predict that the sector will grow to $60 billion by 2010, yielding a compound annual growth rate of 8% over this period. Major changes are however occurring in the oncology market. Cytotoxics, a cornerstone of oncology, are reaching patent expiry and the last cytotoxic genericization is expec
LeadDiscovery

Emerging treatments for inflammatory bowel disease (IBD)

20 Feb 05

Ulcerative colitis and Crohn’s disease, known collectively as inflammatory bowel disease (IBD) currently affects 0.5-1% of the Western world’s population. This translates to over one million people in America (525,000 Ulcerative Colitis, 490,000 Crohn's Disease) and four million people worldwide. Sufferers experience a range of gastrointestinal symptoms, including diarrhea, rectal bleeding and abdominal pain resulting in weight loss as well as other extraintestinal manifestation such as skin and
LeadDiscovery

Alzheimer’s Disease

15 Feb 05

Dementia currently affects over 750,000 people in the UK, with 650,000 new cases arising each year across the European Union. Alzheimer’s disease is the major cause of dementia and accounts for about 55% of all cases. It is a progressive, degenerative disease which affects memory, judgement, orientation, behaviour and language skills, and can place an enormous stress on family caregivers, 49% of whom are over 70 years of age.
CSF Medical Communications

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.